Global Cancer Biological Therapy Market size is expected to reach a valuation of approximately USD 82,276.9 million by the end of 2023, growing at around 4.8 % CAGR over the forecast period.
Major Players In the market are mgen, AbbVie, AstraZeneca, Astellas, Celgene Corporation, Bayer, ELI Lilly & Company, Eisai, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Incyte, Otsuka, Novartis, Sanofi, Pfizer, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, and Seattle Genetics.
Targeted therapy, also called biologic therapy, uses the body's immune system or hormonal system to fight breast cancer cells. The recently approved fam-trastuzumab deruxtecan-nxki (Enhertu) is an antibody treatment for women who have had at least two HER2 treatments before and who are no candidates for surgery. The drug targets changes in HER2.
AbbVie announced on Nov 2020 that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8. They are steadfast in commitment to advancing discovery, innovation and care for people with blood cancers. They are looking forward to sharing findings from expanding hematology oncology portfolio and continued research and treatment advances during the ASH annual meeting.
Nov 2020- AstraZeneca and MSD’s Lynparza has been approved in the European Union (EU) for patients with metastatic castration-resistant prostate cancer with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations. Prostate cancer is the second-most common type of cancer in men, with an estimated 1.3 million patients diagnosed worldwide in 2018.1 approximately 12% of men with mCRPC have a BRCA mutation.2
By Type market has segmented into Vaccines, Cancer growth blockers, Monoclonal antibodies, Cytokines, Blood cell growth factors and Gene therapy. By application, the global cancer biological therapy market is segmented into Cancer Research Centers, Hospitals & Clinics, Laboratories, and others. By Regions, the global cancer biological therapy market is segmented into Europe, Americas, Asia Pacific, Middle East & Africa, and Rest-of-the-World. North America is projected to dominant in future the global cancer biological therapy market throughout the assessment period. The well-developed economy, early uptake of advanced technologies, and high per capita healthcare expenses are the key driving forces for the growth of the regional market.
Further Europe is the key contributors to the overall cancer biological therapy market due to R&D initiatives. Europe is the world’s second-largest market for cancer biological therapy, where the resurging economy and well-proliferated healthcare sectors are the key growth drivers.
For more information contact @